Results 11 to 20 of about 17,568,133 (310)
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
Nature Medicine, 2021 Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial ...Jennifer M. Mitchell, M. Bogenschutz, Alia Lilienstein, C. Harrison, Sarah E. Kleiman, K. Parker-Guilbert, M. Ot’alora G., W. Garas, Casey Paleos, I. Gorman, Christopher R. Nicholas, M. Mithoefer, Shannon Carlin, Bruce Poulter, A. Mithoefer, Sylvestre Quevedo, G. Wells, Sukhpreet Klaire, B. A. van der Kolk, Keren Tzarfaty, R. Amiaz, Ray Worthy, Scott M. Shannon, J. Woolley, C. Marta, Y. Gelfand, Emma Hapke, Simon Amar, Yair Wallach, Randall W. Brown, S. Hamilton, Julie B. Wang, A. Coker, Rebecca Matthews, A. de Boer, B. Yazar-Klosinski, A. Emerson, R. Doblin +37 moresemanticscholar +1 more sourceRemdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
The Lancet, 2020 Background No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human ...Ye-ming Wang, Dingyu Zhang, G. Du, R. Du, Jianping Zhao, Yang Jin, Shouzhi Fu, Ling Gao, Zhenshun Cheng, Q. Lu, Y. Hu, G. Luo, Ke Wang, Yang Lu, Huadong Li, Shuzhen Wang, Shunan Ruan, Chengqing Yang, Chunlin Mei, Yi Wang, Dan Ding, Feng Wu, Xin Tang, X. Ye, Yingchun Ye, Bing Liu, Jie Yang, Wen Yin, Aili Wang, Guohui Fan, F. Zhou, Zhi-bo Liu, Xiaoying Gu, Jiuyang Xu, Lianhan Shang, Yi Zhang, Lianjun Cao, Tingting Guo, Y. Wan, H. Qin, Yushen Jiang, T. Jaki, F. Hayden, P. Horby, B. Cao, Chen Wang +45 moresemanticscholar +1 more sourceSafety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Lancet Neurology, 2021 BACKGROUND
There is an unmet need for treatment options for generalised myasthenia gravis that are effective, targeted, well tolerated, and can be used in a broad population of patients.J. Howard, V. Bril, T. Vu, C. Karam, S. Perić, Temur Margania, H. Murai, M. Bilińska, R. Shakarishvili, M. Śmiłowski, A. Guglietta, P. Ulrichts, T. Vangeneugden, K. Utsugisawa, J. Verschuuren, R. Mantegazza, J. D. De Bleecker, Kathy de Koning, K. De Mey, Annelien De Pue, R. Mercelis, Maren Wyckmans, Caroline Vinck, Linda Wagemaekers, J. Baets, E. Ng, Jafar Shabanpour, Lubna Daniyal, S. Mannan, H. Katzberg, A. Genge, Z. Siddiqi, J. Junkerová, J. Horáková, Katarína Reguliová, M. Týblová, Ivana Jurajdova, I. Nováková, M. Jakubíková, J. Piťha, S. Voháňka, Kateřina Havelková, Tomáš Horák, J. Bednařík, M. Horakova, A. Meisel, Dike Remstedt, Claudia Heibutzki, S. Kohler, L. Gerischer, S. Hoffman, Frauke Stascheit, J. Vissing, Lizzie Zafirakos, Kuldeep Khatri, A. Autzen, Mads Peter Godtfeldt Stemmerik, H. Andersen, S. Attarian, E. Salort-Campana, E. Delmont, Aude-Marie Grapperon, L. Kouton, A. Tsiskaridze, C. Rózsa, G. Jakab, Szilvia Tóth, Györgyi Szabó, David Bors, Enikö Szabó, A. Campanella, F. Vanoli, R. Frangiamore, C. Antozzi, S. Bonanno, L. Maggi, R. Giossi, F. Saccà, A. Marsili, Chiara Pane, G. Puorro, A. Reia, G. Antonini, G. Alfieri, S. Morino, M. Garibaldi, L. Fionda, L. Leonardi, S. Konno, A. Uzawa, Kaoru Sakuma, C. Watanabe, Y. Ozawa, M. Yasuda, Yosuke Onishi, M. Samukawa, Tomoko Tsuda, Yasushi Suzuki, Sayaka Ishida, G. Watanabe, Masanori Takahashi, Hiroko Nakamura, E. Sugano, T. Kubota, T. Imai, M. Suzuki, A. Mori, D. Yamamoto, Kazuna Ikeda, S. Hisahara, M. Masuda, Miki Takaki, Kanako Minemoto, N. Ido, Makiko Naito, Y. Okubo, T. Sugimoto, Yuka Takematsu, Ayumi Kamei, M. Shimizu, H. Naito, E. Nomura, Marjolein Van Heur, A. Peters, M. Tannemaat, A. Ruiter, K. Keene, M. Hałas, A. Szczudlik, Marta Pinkosz, Monika Frasinska, G. Zwolińska, A. Kostera-Pruszczyk, Aleksandra Golenia, Piotr Szczudlik, L. Szczechowski, A. Paśko, I. Poverennova, Lubov Urtaeva, N. Kuznetsova, T. Romanova, M. Nadezhda, Elena Lapochka, Denis Korobko, I. Vergunova, Anna D. Melnikova, Ekaterina Bulatova, E. Antipenko, I. Basta, I. Božović, D. Lavrnić, V. Stojanović, S. Beydoun, S. Akhter, A. Malekniazi, Leila Darki, Norianne Pimentel, Victoria Cannon, M. Chopra, Rebecca E. Traub, T. Mozaffar, Isela Hernández, I. Turner, A. Habib, Namita A. Goyal, Manisha Kak, Erik Velásquez, Lucy Lam, Niraja Suresh, J. Farias, S. Jones, M. Wagoner, Debbie Eggleston, T. Bertorini, C. Benzel, R. Henegar, Rekha Pillai, Ratna Bharavaju-Sanka, Carolyn Paiz, Carlayne Jackson, Katherine Ruzhansky, D. Dimitrova, Amy C. Visser, Nizar Chahin, T. Levine, R. Lisak, K. Jia, Flicia Mada, E. Bernitsas, M. Pasnoor, Katherine Roath, S. Colgan, M. Currence, A. Heim, R. Barohn, M. Dimachkie, J. Statland, O. Jawdat, D. Jabari, C. Farmakidis, J. Gilchrist, Yuebing Li, Irys B Caristo, Debbie Hastings, J. Morren, Michael Weiss, S. Muppidi, T. Nguyen, Lesly Welsh, Y. So, Neelam Goyal, M. Pulley, C. Bailey, Zubair Quraishi, A. Berger, G. Sahagian, Yasmin Camberos, B. Frishberg +217 moresemanticscholar +1 more sourceA Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
New England Journal of Medicine, 2020 BACKGROUND
Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited.P. Newsome, Kristine Buchholtz, K. Cusi, Martin Linder, T. Okanoue, V. Ratziu, A. Sanyal, A. Sejling, S. Harrison +8 moresemanticscholar +1 more sourceSafety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Lancet. Infectious Diseases (Print), 2020 Background With the unprecedented morbidity and mortality associated with the COVID-19 pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac (Sinovac Life Sciences, Beijing, China), an inactivated vaccine candidate against ...Yanjun Zhang, G. Zeng, H. Pan, Changgui Li, Yaling Hu, K. Chu, W. Han, Zhen Chen, R. Tang, W. Yin, Xin Chen, Yuansheng Hu, Xiaoyong Liu, Congbing Jiang, Jing-xin Li, Minnan Yang, Yan Song, Xiangxi Wang, Q. Gao, F. Zhu +19 moresemanticscholar +1 more sourceIvosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
The Lancet Oncology, 2020 BACKGROUND
Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of patients with intrahepatic cholangiocarcinoma, a relatively uncommon cancer with a poor clinical outcome.G. Abou-Alfa, T. Macarulla, M. Javle, R. Kelley, S. Lubner, J. Adeva, J. Cleary, D. Catenacci, M. Borad, J. Bridgewater, W. Harris, A. Murphy, D. Oh, J. Whisenant, M. Lowery, L. Goyal, R. Shroff, A. El-Khoueiry, Bin Fan, Bin Wu, Christina X. Chamberlain, Liewen Jiang, C. Gliser, S. Pandya, J. Valle, A. Zhu +25 moresemanticscholar +1 more sourceA MULTICENTER, BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF THE SYMPTOM- AND STRUCTURE-MODIFYING EFFET OF ALFLUTOP IN PATIENTS WITH KNEE OSTEOARTHRITIS. REPORT 2: THE ASSESSMENT OF THE STRUCTURE-MODIFYING EFFECT OF THE DRUG
Научно-практическая ревматология, 2014 Objective. To evaluate the symptom- and structure-modifying effect of Alflutop compared to placebo (PL) in patients with knee osteoarthritis (OA). Material and methods. The study included 90 patients with knee OA (according to the criteria of the Russian L. I. Alekseeva, E. P. Sharapova, E. A. Taskina, N. V. Chichasova, G. R. Imametdinova, N. A. Shostak, N. G. Pravdyuk, L. N. Denisov +7 moredoaj +1 more sourceMavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
The Lancet, 2020 BACKGROUND
Cardiac muscle hypercontractility is a key pathophysiological abnormality in hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow tract (LVOT) obstruction.I. Olivotto, A. Oreziak, R. Barriales-Villa, Theodore P Abraham, A. Masri, P. García-Pavía, S. Saberi, Neal K. Lakdawala, M. Wheeler, A. Owens, M. Kubanek, W. Wojakowski, M. Jensen, J. Gimeno-Blanes, K. Afshar, J. Myers, Sheila M. Hegde, S. Solomon, A. Sehnert, David X. Zhang, Wanying Li, Mondira Bhattacharya, J. Edelberg, C. Waldman, Steven J. Lester, Andrew Wang, Carolyn Y. Ho, D. Jacoby +27 moresemanticscholar +1 more source
